Tuesday 3 March 2020

Fibrocystic Breasts Diagnostics and Treatment Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2023

More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.
The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).
Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 
Key Players
Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.
Regional Analysis
In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.
The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Segmentation
The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Verrucous Carcinoma Market Growth Trends, Size Estimation, Industry Analysis, Sales Statistics, Global Share, Leading Key Players and Regional Forecast 2023

Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest Verrucous Carcinoma market share in the global market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.
Browse more Life Sciences Reports @ https://www.marketresearchfuture.com/categories/life-sciences-market-report
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:
Labels:

Sacroiliitis Market Size, Share, Development, Growth and Demand Forecast to 2023

Market Scenario
The Global Sacroiliitis Treatment Market is expected to witness tremendous growth during the forecast period. The growing prevalence of arthritis increase in traumatic injuries, growing prevalence of spondylitis, increased research on joint health and joint conditions, and adoption of technologically-advanced systems are the key factors for the market to grow. However, factors such as high cost of diagnostics and treatment and surgical procedures are expected to restrict the market growth during the forecast period.
According to the Centers for Disease Control and Prevention (2013to 2015), 22.7% Americans of the total population had arthritis, annually. Thus, such a high prevalence of arthritis and increasing government funding for the healthcare sector enhance the growth of this market.
However, factors such as expensive diagnostic tests and the high cost of surgical procedures are expected to restrict the market growth during the forecast period.
Key players
  • Medacta International,
  • SI-BONE,
  • Globus Medical,
  • Zyga Technology,
  • Nutech Medical,
  • CoorsTek Medical LLC,
  • Aspen Medical Products,
Segmentation
The Global Sacroiliitis Market is segmented on the basis of diagnosis, treatment, and end-user. The sacroiliitis market, by diagnosis, is sub-segmented into imaging tests and anesthetic injections. The imaging tests category includes x-ray, MRI, and CT scan. On the basis of treatment, the market is categorized into medications, joint injections, radiofrequency denervation, electrical stimulation, joint fusion, facet block, chiropractic manipulation, and physical therapy. On the basis of end-user, the market is segmented into hospitals and clinics, pharmacies, and diagnostic centers.
On the basis of region, the global sacroiliitis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Analysis
The Sacroiliitis Market is dominated by North America owing to the high prevalence of arthritis and high healthcare investments within this region. According to the Centers for Disease Control and Prevention by 2040, 78.4 million will have doctor-diagnosed arthritis.The rising adoption of technologically advanced systems for early diagnosis of diseases also drives the market growth in this region.
Asia-Pacific was projected to be the fastest growing region for the Global Sacroiliitis Market. Key factors such as the growing patient pool, the high prevalence of chronic diseases, developing healthcare infrastructure, and increasing research and development activities in the biotechnology sector influence the market in this region. The presence of major market players such as China, India, and Japan drives the market growth.
It is estimated that Europe stood second in the Global Sacroiliitis Market. The increasing prevalence of lower back disorders and the availability of minimally invasive surgical procedures for Sacroiliitis drive the market growth in this region. According to The European (2015), sacroiliac joint was the main reason for chronic low back pain in Europe.
The Middle East and Africa holds the least share of the Global Sacroiliitis Market due to the presence of stringent government policies and poor economies. However, growing awareness among the population, rising government initiatives to improve the healthcare sector, and high investments by private market players in this region can boost the market growth. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Digital Wound Measurement Devices Market Growth Trends, Size Estimation, Industry Analysis, Sales Statistics, Global Share, Leading Key Players and Regional Forecast 2023

The global digital wound measurement devices market is expected to witness a positive growth during the forecast period. Digital wound measurement devices enable monitoring of chronic wounds and deliver the appropriate drug dose to speed up the process of healing. Chronic wounds if not treated on time can lead to severe infections and amputations. Hence, digital wound measurement devices allow delivering tailored treatments after the 2D or 3D assessment of the infection and inflammation. The increasing number of patients suffering from chronic wounds drives the market growth. According to the Intermountain Healthcare (2017), 6.5 million people in the US suffer from chronic wounds. Diabetic wounds are severe, and the process of healing is very long and eventually may lead to amputations. Hence factors such as growing diabetic patients, rising geriatric population, and an increasing number of surgeries are major factors influencing the growth of the market. The emergence of smartphones, rapid use of advanced digital tools, and the advent of telehealth for wound care will also contribute for the market to grow.
However, factors such as, the inability of the device to provide additional information about wounds such as moistness or exudation and high costs of digital devices are expected to restrict the market growth during the forecast period.
Key Players
  • WoundRight Technologies Tissue Analytics
  • Parable Health
  • ARANZ Medical Limited
  • eKare, Inc,
  • KCI,
  • an Acelity Company,
  • WoundMatrix, Inc.,
  • WoundZoom Inc.,
  • Kent Imaging Inc.,
  • WoundRight Technologies, LLC,
  • WoundVision, LLC,
  • Hitachi Healthcare Americas,
  • Smith & Nephew plc.
Segmentation
The global digital wound measurement devices market is segmented on the basis of wound type, product, and end-user. The digital wound measurement devices market, by wound type is sub-segmented into a diabetic ulcer, chronic wounds, burns, incisional, and traumatic. The product segment is sub-segmented into contact wound measuring devices and non-contact wound measuring devices.
On the basis of end-user, the market is segmented into hospitals, clinics, and ambulatory surgical centers.
On the basis of region, the global digital wound measurement devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Market
Asia-Pacific was projected to be the fastest growing region for the global digital wound measurement devices market demand. Key factors such as rising geriatric population, growing diabetic patient pool, high incidence chronic wounds, and developing healthcare infrastructure drive the market in this region. According to the Asian Diabetes Prevention Initiative, 60% of the world diabetic population is in Asia. This provides favorable backgrounds for the market to grow in Asia.
The digital wound measurement devices market is dominated by North America owing to the rising prevalence of chronic wounds and technological advancements in the healthcare sector.  In June 2018, KCI, an Acelity Company announced the launch of Nurse2Nurse (N2N) Mobile App for wound care nurses. The app allows interactions with clinicians and shares credible insights and information for better patient care.
It is estimated that Europe was the second largest in the global digital wound measurement devices market. The increasing technological advancement and research for wound care along with government support in Europe drive the market growth in this region. The European Wound Management Association will conduct its 29th conference by June 2019 in Gothenburg, Sweden in the presence of several international wound management communities with the common goal of improving the care of wound patients.
The Middle East and Africa holds the least share of the global digital wound measurement devices market due to the presence of stringent government policies and poor economic growth. However, growing awareness and increasing investments by private market players in this region can boost the market growth. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Coronary Stent Market: 2019 Global Size, Trends, Investments, Share, Leading Players, Merger, Acquisition, Growth Factors, Regional Analysis, And Industry Forecast To 2023

The global coronary stents market is projected to touch USD 9,382.63 million at a stupendous 7.81% CAGR over the predicted years (2018-2023). Coronary stents are utilized in angioplasty for making cross-section of blood vessels wider. The stent will reduce the chest pain along with recovering survivability during acute myocardial infarction. Coronary stents are used for treating cardiac diseases namely coronary artery disease, angina pain and myocardial infarction.
There are many factors that is driving the growth of the coronary stents market share. Some of these factors as per the Market Research Future (MRFR) report include increasing prevalence of CAD (coronary artery disease, innovations in coronary stents, increase in research and development of coronary stems, untapped emerging countries offering new market opportunities, lifestyle change diseases, increasing geriatric population, profound increase in healthcare coverage, advanced medical technologies, development of ICT (information and communication technology) and increase in government investment. On the contrary, factors such as high expenditure of procedures related to coronary stents coupled with accessibility of substitutes for CAD treatment is likely to hinder the growth of the coronary stents market.
Market Segmentation
Market Research Future report offers an all-inclusive segmental analysis of the coronary stents market on the basis of products and end user.
Based on products, it is segmented into Bioresorbable Vascular Scaffolds, Bare Metal Stents and Drug Eluting Stents. Of these, drug eluting stent is expected to lead the market during the predicted years owing to its increasing acceptance in better patient compliance, angioplasty procedures in comparison to bare metal stents. The bioresorbable stents is expected to expand at the fastest pace.
Based on end users, the coronary stents market is segmented into specialty centers, ambulatory surgical centers, hospitals and clinics and others. Of these, hospitals and clinics will have the maximum market share during the predicted years. This will be followed by the ambulatory surgical centers which will expand at the fastest rate.
Regional Analysis
Based on region, the coronary stents market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America will have a lion’s share in the market due to increasing cases of cardiovascular diseases mainly coronary artery disease, arterial blockage, cardiac arrythmia to name a few. Availability of advanced treatment methods and better therapeutic approaches has affected the growth of the market in this region in a positive way. The other factors that is driving the growth of the coronary stents market here include high disposable income, increasing medical awareness among the people here and existence of leading medical device manufacturers in this region. The coronary stents market in Europe holds the second largest share owing to the increasing support by the government for device manufacturers. Also, expansion of the companies geographically has resulted in a broader reach of medical services and products that has brought tremendous change with regards to acceptance as well as implementation of novel procedures and products. The coronary stents market in the APAC region experienced a huge growth due to the increasing development in the medical domain in the developing countries such as China and India. Besides, increasing medical device companies here, increasing research and development expenditure and increasing funding made by the government has resulted in its fastest growth. On the other hand, the coronary stents market in the Middle East and Africa is expected to have minimal growth opportunities.
Competitive Analysis
The coronary stents market is fragmented and highly competitive. The leading companies which have used strategies such as strategic alliances and mergers and acquisitions have gained a competitive advantage. Besides companies are highly focused to create products that are technologically advanced and deliver efficiency and greater accuracy.
Key Players
Leading players profiled in the coronary stents market include Terumo Corporation, Stentys SA, MicroPort Scientific Corporation, Meril Life Sciences, Medtronic plc, Elixir Medical Corporation, Cook Medical, R. Bard, Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, and Abbott, B. Braun Melsungen AG.
Feb 2019- Biotronik has received approval from the FDA on its Ultrathin Orsiro Stent to treat coronary artery disease. This coronary stent will offer a novel treatment option to healthcare providers that will help in sealing the perforation to prevent blood leakage at the time of the procedure as well as avoid higher invasive surgical procedure or life-threatening complication.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Refsum Disease Market Growth Trends, Size Estimation, Industry Analysis, Sales Statistics, Global Share, Leading Key Players and Regional Forecast 2023

Refsum disease is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene that metabolizes phytanic acid. According to the U.S. National Library of Medicine, more than 90 % cases of refsum disease result from the mutations in PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably, increasing awareness among people is the key factor driving the refsum disease market. According to the National Organization of Rare Diseases, the age of onset of refsum disorder varies greatly. The disease can occur at any time from early childhood to nearly 50 years of age, but in most cases will have appeared by age 20. Males and females are equally affected in numbers.
Various other push factors such as increasing awareness among people, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global refsum disease market.
Despite these drivers, there are some issues associated with refsum disease market. Some of the challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the market to some extent.
It is estimated that the refsum disease market is expected to grow at a CAGR 5.4% during the forecast period of 2019-2023.
Key Players
  • Fresenius Kabi,
  • Braun Medical Inc.,
  • Medline Industries, Inc.,
  • Illumina, Inc.,
  • Igenomix,
  • Ceuta Healthcare Limited,
  • Cochlear Ltd.,
  • Cook,
  • Sonova,
  • William Demant Holding A/S,
  • Nurotron Biotechnology Co. Ltd.,
  • Agilent Technologies,
  • Bio-Rad Laboratories, Inc.,
Segmentation
The global refsum disease market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into adult refsum disease, and others. The adult refsum disease is further segmented into adult refsum disease 1, and adult refsum disease 2.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into diet, plasmapheresis, and medication. The sub-segments of medication include keratolytics, and others.
On the basis of the diagnosis, the market is classified into physical examination, molecular genetic testing, prenatal screening tests, preimplantation genetic diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic testing is further segmented into genotyping, sequencing of gene, amplification or hybridization method, methylation-specific techniques, and others. The prenatal screening tests are further segmented into ultrasound, blood tests, chorionic villus sampling (CVS), amniocentesis, and others.
On the basis of the end-user, the market is segmented into hospital, clinics, diagnostic centers, research & academic institutes, and others.
Regional Analysis
The Asia Pacific is the fastest growing refsum disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Americas dominate the refsum disease market owing to the rising awareness among people and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the refsum disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in healthcare is likely to drive the market of the European region.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Spongiform Encephalopathy Market Growth Trends, Size Estimation, Industry Analysis, Sales Statistics, Global Share, Leading Key Players and Regional Forecast 2023

Market Scenario
Transmissible spongiform encephalopathy (TSEs) or prion diseases are a group of invariably fatal conditions that affect central nervous system (CNS) and more specifically the brain and spinal cord. The most commonly known prion diseases in human are Fatal Familial Insomnia, Creutzfeldt - Jakob disease (CJD), Gerstmann-Straussler-Scheinker Syndrome, and Kuru, and most commonly identified animal prion diseases are Transmissible mink encephalopathy, Bovine Spongiform Encephalopathy (BSE), Scrapie, and others.
BSE (bovine spongiform encephalopathy) is one of the most common neurological disorder found in cattle that results from a transmissible agent called a prion. According to the Centers for Disease Control and Prevention, five cases of BSE are found in the U.S. and 20 in Canada in 2017.
A number of factors such as rising facilities for patients affected by encephalopathy, increasing awareness among people, increasing government assistance, and improvement in regulatory framework are propelling the growth of the global spongiform encephalopathy market.
Despite these drivers, challenges in research and development, and poor healthcare system in low and middle-income countries may hamper the growth of the market.
It is estimated that spongiform encephalopathy market expected to grow at a healthy CAGR of 6.1% during the forecast period 2017-2023.
Key Players
Teva Pharmaceuticals, Abbvie, Adamas Pharmaceuticals, Inc., Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific Inc., and others.
Regional Analysis
The Asia Pacific is the fastest growing spongiform encephalopathy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the year 2014-15.
Europe dominates the spongiform encephalopathy market owing to the high prevalence of bovine spongiform encephalopathy in European region, support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region
The Americas hold the second position in the spongiform encephalopathy market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
The Middle East & Africa owns the least share of the global spongiform encephalopathy market due to lack of technical knowledge and poor medical facilities.
Segmentation
The spongiform encephalopathy market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into in humans, in animals. The human's segment is classified into Creutzfeldt-Jakob disease, Variant Creutzfeldt-Jakob disease (vCJD), others. The others segment includes Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, and kuru (Papua New Guinea). The animals segment is classified into bovine spongiform encephalopathy (BSE), Scrapie in sheep and goats, Chronic Wasting Disease (CWD), Feline spongiform encephalopathy, others. BSE is further classified into classical BSE and atypical BSE.
On the basis of the diagnosis, the market is classified into histopathology and immunohistochemistry, immunochemical detection methods, animal bioassays, cell culture assay systems, protein misfolding cyclic amplification, conformation-dependent immunoassay, capillary electrophoresis, fluorescent correlation spectroscopy, multispectral ultraviolet fluorescence spectroscopy, and Fourier transform infrared spectroscopy. Histopathology and Immunohistochemistry are further segmented into immunohistochemical staining and electron microscopy. Immunochemical Detection Methods is further segmented into Western Blotting Test, and Enzyme-Linked Immunosorbent Assay (ELISA).
On the basis of the treatment, the market is classified into small molecules, and immunotherapies. The small molecules are further classified into pentosan polysulfate, quinacrine, amphotericin B, and others. Immunotherapies are further classified into Antibody-based immunotherapies and Cell-Based Immunotherapies. Antibody-based immunotherapies include passive immunization, active immunization, and targeting disease-specific epitopes. Cell-based immunotherapies include DC vaccines and adoptive transfer of CD4+ T-cells.
On the basis of the end-users, the market is segmented into hospital & clinics, diagnostic centers veterinary hospitals, research & academic laboratories, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)